Your browser doesn't support javascript.
loading
Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study.
Omran, Meis; Johansson, Hemming; Lundgren, Claudia; Silander, Gustav; Stenmark-Askmalm, Marie; Loman, Niklas; Baan, Annika; Adra, Jamila; Kuchinskaya, Ekaterina; Blomqvist, Lennart; Tham, Emma; Bajalica-Lagercrantz, Svetlana; Brandberg, Yvonne.
Afiliación
  • Omran M; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Johansson H; Cancer Theme, Karolinska University Hospital Solna, Stockholm, Sweden.
  • Lundgren C; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Silander G; Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden.
  • Stenmark-Askmalm M; Department of Radiation Sciences, Umeå University, Umeå, Sweden.
  • Loman N; Division of Clinical Genetics, Department of Laboratory Medicine, Office for Medical Services, Skåne University Hospital, Lund, Sweden.
  • Baan A; Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
  • Adra J; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden.
  • Kuchinskaya E; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Blomqvist L; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Tham E; Department of Clinical Genetics, Linköping University Hospital, Linköping, Sweden.
  • Bajalica-Lagercrantz S; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Brandberg Y; Department of Imaging and Physiology, Karolinska University Hospital Solna, Stockholm, Sweden.
Cancer ; 129(6): 946-955, 2023 03 15.
Article en En | MEDLINE | ID: mdl-36601958
ABSTRACT

BACKGROUND:

To evaluate the psychosocial consequences of surveillance with whole-body MRI (WB-MRI) in individuals with the heritable TP53-related cancer (hTP53rc) syndrome, also known as the Li-Fraumeni syndrome, with regard to cancer worry, perceived benefits and risks to surveillance and overall health. PATIENTS AND

METHODS:

Since 2016, the national Swedish TP53 Study (SWEP53) has offered surveillance with WB-MRI to all individuals with hTP53rc syndrome. Seventy-five individuals have been included in the study. Sixty consecutive participants fulfilled a base-line evaluation as well as an evaluation after 1 year with structured questionnaires including the Cancer Worry Scale (CWS), perceived benefits and risks of surveillance, and the 36-item Short Form Survey (SF-36). Individuals with or without previous personal cancer diagnosis were enrolled and results at baseline and after 1 year of surveillance were compared. For SF-36, a comparison with the normal population was also made.

RESULTS:

Participants with previous cancer tend to worry more about cancer, but both individuals with and without cancer had a positive attitude toward surveillance with no differences regarding perceived benefits and barriers to surveillance. Participants with a previous cancer scored significantly lower on some of the SF-36 subscales, but between-group differences were found only for social functioning after 1 year.

CONCLUSIONS:

Surveillance with WB-MRI is feasible from a psychosocial point of view both among TP53 carriers with as well as without a previous history of cancer and does not increase cancer worry in any of the groups. PLAIN LANGUAGE

SUMMARY:

Individuals with heritable TP53-related cancer syndrome (also known as the Li-Fraumeni syndrome) have a high lifetime risk of developing cancer. These TP53 carriers are offered surveillance with whole-body MRI to detect cancer early. There are few reports of the psychosocial impact of surveillance. In this study, we wanted to evaluate cancer worry, benefits and barriers to participation, and perceived overall health. Our study shows no increase in cancer worry after 1 year of surveillance, regardless of previous cancer.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndrome de Li-Fraumeni Tipo de estudio: Qualitative_research / Screening_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Cancer Año: 2023 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndrome de Li-Fraumeni Tipo de estudio: Qualitative_research / Screening_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Cancer Año: 2023 Tipo del documento: Article País de afiliación: Suecia